The new drug application (NDA) is supported by results from a two-year, double-blind, placebo-controlled, randomized Phase III clinical trial of 1,382 men with advanced prostate cancer on androgen
The company expects to raise $320 million in aggregate gross proceeds from the common stock offering. Merrill Lynch & Company is acting as the sole book-runner, with Cowen
BioAlliance Pharma, a specialty pharmaceutical company, has initiated its European marketing application for ondansetron RapidFilm, the fast-dissolving oral film strip formulation of ondansetron. According to the company, this
Vion Pharmaceuticals, a developer of therapeutics for the treatment of cancer, has filed a new drug application with the FDA for its lead oncology therapeutic Onrigin injection as
Ark Therapeutics, a specialist healthcare company, has announced that the first named patient supply for Cerepro has been approved by the French Medicines Control Agency following a ‘nominative’
Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical, a member of the Roche Group, have entered into an exclusive licensing agreement for the development and commercialisation
In addition to this capacity, Sheares was a member of Merck’s management committee, which was responsible for formulating global business strategies, managing operations and setting corporate policies. He
The company reported fourth quarter 2008 revenue of $26.7 million, up 22% over revenue of $21.9 million in the fourth quarter of 2007, and record full year revenue
Mr Longhini joined the company in 2003 as executive vice president and chief technology officer and in 2006 was promoted to executive vice president and COO. Mr Longhini
The price to be paid for the common stock, $7.13 per share, is equal to the consolidated closing bid price on the Nasdaq global market on the day
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.